title: Trends in antifungal research.
abstract: With the increasing use of aggressive immunosuppressive therapies in the management of a variety of patient populations, the continuing presence of the AIDS pandemic and the therapeutic advances employed in critical care settings, an increasing number of serious fungal infections are being encountered by today's practicing clinicians. Traditionally, antifungal drug therapy has been delivered by means of intravenous infusion, oral administration, or topical application. Recently, a number of alternative routes of antifungal drug delivery have been developed and investigated, and the traditional means of antifungal administration have been improved to facilitate the therapeutic use of new and reformulated antifungal agents. Organized based on the route of administration, this chapter reviews these advances in antifungal drug delivery.
authors.affiliation: College of Pharmacy, University of Texas at Austin, USA.
authors.forename: V
authors.initials: V
authors.lastname: Mahaguna
authors.forename: R O
authors.initials: RO
authors.lastname: Williams
authors.forename: T C
authors.initials: TC
authors.lastname: Hardin
mesh_terms: D000281:Administration, Intranasal; D000282:Administration, Intravaginal; D000284:Administration, Oral; D000287:Administration, Topical; D000336:Aerosols; D000935:Antifungal Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D004655:Emulsions; D005260:Female; D006801:Humans; D007267:Injections; D008081:Liposomes; D008823:Micelles; D008863:Microspheres; D009181:Mycoses / Q000188:drug therapy; D009883:Ophthalmic Solutions; D012106:Research / Q000639:trends; D013488:Suppositories
chemical_list: D000336:Aerosols; D000935:Antifungal Agents; D004655:Emulsions; D008081:Liposomes; D008823:Micelles; D009883:Ophthalmic Solutions; D013488:Suppositories